DERM Dermira Inc.

8.06
+0.01  (+0%)
Previous Close 8.05
Open 8.06
Price To Book 6.66
Market Cap 438,447,517
Shares 54,397,955
Volume 240,303
Short Ratio
Av. Daily Volume 589,673

NewsSee all news

  1. Dermira to Participate in Upcoming Investor Conferences

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 5, 2018 - failed to meet all co-primary endpoints.
Olumacostat glasaretil (DRM01)
Acne
Approval announced June 29, 2018.
Glycopyrronium tosylate
Primary axillary hyperhidrosis
Phase 3 trial to be initiated later in 2019.
Lebrikizumab
Atopic Dermatitis
Proof of concept initiation announced February 22, 2019 with data due 2H 2019.
QBREXZA (glycopyrronium)
Primary palmar hyperhidrosis

Latest News

  1. Dermira to Participate in Upcoming Investor Conferences

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin